Sam­sung Bio’s bet on Plant 4 con­tin­ues to pay off with first-quar­ter earn­ings growth

Sam­sung Bi­o­log­ics’ Plant 4 re­mains a worth­while $2 bil­lion in­vest­ment.

The CD­MO said that the fa­cil­i­ty was key in its first-quar­ter gains and will con­tin­ue to be for the rest of the year. Al­though the South Ko­re­an com­pa­ny did not break down its rev­enue by fa­cil­i­ty, it said on Wednes­day that much of its Q1 earn­ings at 946.9 bil­lion Ko­re­an won ($690 mil­lion) were due to Plant 4 and its biosim­i­lar busi­ness — a 31% in­crease from the 720.9 bil­lion Ko­re­an won ($525 mil­lion) it re­port­ed in Q1 last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER